Wednesday, February 1, 2012

Impax nabs AstraZeneca migraine drug, will hire 20 people

Impax Laboratories Inc. will add 20 people to its sales force, it said Wednesday, after licensing the AstraZeneca migraine drug Zomig for $130 million.
The move beefs up the branded products pipeline of Hayward-based Impax (NASDAQ: IPXL), known more for marketing low-cost generic drugs. But the deal with AstraZeneca (NYSE: AZN) could tie in to Impax’s generic business — it has focused on controlled-release generics and could apply the same technology with Zomig.

No comments:

Post a Comment